Expression of the C-terminal flanking peptide of human progastrin in human gastroduodenal mucosa, G-cell hyperplasia and islet cell tumours producing gastrin

M. Hara, I. M. Varndell, A. E. Bishop, M. Aitchison,* J. Rode,†
T. Yamada,‡ D. M. Green,§ S. R. Bloom and J. M. Polak

Departments of Histochemistry and Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK,
*Department of Surgery, Inverclyde Royal Hospital, Greenock, Scotland, UK,
†Bland-Sutton Institute of Pathology, The Middlesex Hospital Medical School, London W1P 7PN, UK,
‡Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA, and
§Department of Pathology, University of Leeds, Leeds LS2 9JT, UK

(Received 18 November 1986, Accepted 21 January 1987)

Three antisera to the C-terminally extended form of gastrin or the C-terminal flanking peptide of progastrin were used in an attempt to investigate the post-translational processing of progastrin at the cellular level by light and electron microscopical immunocytochemistry.

In the normal human gastric antrum, the G-cell secretory granules were found to contain both gastrin and the C-terminal progastrin determinants (progastrin 87–93, 87–95 and 93–101). Immunostaining of serial sections at the light microscopical level revealed that duodenal gastrin-containing cells also express the C-terminal progastrin determinants, as well as gastrin-34. In foetal tissue, cells containing C-terminal gastrin and the C-flanking peptide of progastrin were first seen at 8 weeks of gestation, in the duodenum. They were not found in the stomach until the 11th week. In hyperplastic G-cells and in gastrin-producing tumour cells, the level of C-terminal peptide immunoreactivity was variable and often lower than that seen in normal antrum and only minimal immunoreactivity could be detected using electron immunocytochemistry. This was interpreted as representing altered post-translational processing of progastrin in modified G-cells.

KEYWORDS: Gastrin, C-terminal peptide of progastrin, immunocytochemistry, electron microscopy, G-cell hyperplasia, gastrin-producing tumours.

Address for all correspondence: Professor J. M. Polak, Department of Histochemistry, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.

0890-8508/87/010095 + 14 $03.00/0 © 1987 Academic Press Inc. (London) Ltd
INTRODUCTION

Most, if not all, bioactive peptides are derived from larger precursor molecules (prohormones) by proteolytic cleavage at sites characterized by the presence of dibasic amino acid residues. Indeed, many prohormones have been found to contain multiple peptide sequences, limited by potential cleavage sites, a number of which may effect a biological function, for example pro-opiomelanocortin (POMC) contains the sequences of ACTH, endorphin, βLPH, MSH and CLIP and pro-glucagon those of glucagon, glucagon-related pancreatic peptide, glicentin, glucagon-like peptides 1 and 2. As the post-translational enzymatic cleavage of the prohormones may be activated differentially by tissue-specific mediators, it is necessary to determine which sequences are elaborated by each prohormone-containing endocrine cell type.

Endocrine cells typically contain secretory granules with varied morphology which is thought to reflect storage of different molecular forms of bioactive peptides produced during post-translational processing. The mammalian G-cell has been shown to contain two main granule populations. We have previously investigated the processing of gastrin in human G-cells and shown that these two populations, in fact, correspond to the extremes of the granular maturation process. Immature, small electron-dense granules contain both G17 and G34 whilst the intermediate forms of pale-cored granules have G17 alone. The large, electron-lucent granules show little or no gastrin immunoreactivity.

More recently, the structure of progastrin has been deduced from the nucleotide sequence of mRNA cloned from porcine gastric antrum, human gastric antrum and human pancreatic gastrin-producing tumours (Zollinger–Ellison syndrome). Human progastrin consists of 101 amino acids, within which is a single copy of gastrin-34 (‘big gastrin’, G34; Fig. 1). A nine amino acid sequence (-Gly-Arg-Arg-Ser-Ala-Glu-Asp-Glu-Asn) flanks G34 at the C-terminal of the precursor. We have used antisera raised against three synthetic regions of this flanking peptide (see Table 1) in an immunocytochemical study in order to determine the intracellular localization of the C-terminal peptide in normal human stomach and duodenum (developing and adult), stomach with G-cell hyperplasia and in pancreatic tumours producing gastrin.

Fig. 1. Diagram of the human progastrin molecule showing the positions of G34, G17 and PSN.
Table 1. Amino acid sequences of the peptides synthesized for antibody production

<table>
<thead>
<tr>
<th>Description</th>
<th>Amino acid sequence</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human progastrin sequence 87–101</td>
<td>Tyr Gly Trp Met Asp Phe Gly Arg Arg Ser Ala Glu Asp Glu Asn</td>
<td>For reference</td>
</tr>
<tr>
<td>Progastrin 87–93</td>
<td>Try Gly Trp Met Asp Phe Gly</td>
<td>GL7</td>
</tr>
<tr>
<td>Progastrin 87–95</td>
<td>Try Gly Trp Met Asp Phe Gly Arg</td>
<td>GL9</td>
</tr>
<tr>
<td>Progastrin 96–101</td>
<td>Ser Ala Glu Asp Glu Asn</td>
<td>PSN</td>
</tr>
<tr>
<td>Rat Pro–CCK 96–104</td>
<td>Ser Ala Glu Asp Tyr Glu Tyr Pro Ser Tyr Pro Ser</td>
<td>PSS</td>
</tr>
<tr>
<td>Human G17</td>
<td>Gln Gly Pro Trp Leu Glu Glu Glu Glu Ala Tyr Gly</td>
<td></td>
</tr>
<tr>
<td>Human G34</td>
<td>Trp Met Asp Phe Gly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gln Leu Gly Pro Glu Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys Lys–G17</td>
<td></td>
</tr>
</tbody>
</table>

* Antiserum cross-reacts extensively with cholecystokinin (CCK), will recognize G34.
† Antiserum does not cross-react with CCK or G17.
MATERIALS AND METHODS

Tissues

Specimens of gastric antrum \((n = 3)\), duodenum \((n = 5)\) and pancreatic islet cell tumours producing gastrin \((n = 6)\) were obtained at surgery. Endoscopic biopsy specimens of gastric antrum from patients with pernicious anaemia \((n = 10)\) were obtained by endoscopy. The stomachs from 25 foetuses \((8–28\) weeks' gestation) were collected at legal terminations of pregnancy or from spontaneous abortions.

Light microscopy

Tissues were fixed in Bouin's solution or 10% neutral-buffered formalin, embedded in paraffin wax and sectioned at 5 \(\mu m\). For co-localization studies some fixed tissue was embedded in epoxy resin (see Electron microscopy below) and serially sectioned at 0.5–1.0 \(\mu m\).

Light microscopical immunocytochemistry

Immunocytochemical studies were performed using the peroxidase anti-peroxidase (PAP) technique. Sections were de-waxed in inhibisol or de-resinated in sodium alkoxide and brought to phosphate-buffered saline (PBS, pH 7.2).

Endogenous peroxidatic activity and non-specific staining were blocked by incubation for 30 min in 0.3% hydrogen peroxide in PBS followed by a further 10 min in normal goat serum (1:30 dilution in PBS).

The primary antisera were applied for 16–24 h at 4°C in a moist atmosphere. Full details of the primary antisera are given in Tables 1 and 2. After thorough rinsing in PBS, a second layer, goat anti-rabbit IgG antiserum (Miles Labs, Stoke Poges, UK) was applied for 30 min at 1:200. Following further rinses in PBS, the sections were incubated with rabbit PAP complex (Miles Labs) for 30 min at 1:400 dilution. Localization of the PAP complex was achieved using a solution of 3,3'-diaminobenzidine tetrahydrochloride (0.025%) and hydrogen peroxide 0.01% in PBS for 5–8 min. After development of the reaction product the sections were dehydrated through graded ethanol to xylene, mounted in DPX and examined with a transmitted light microscope.

Electron microscopy

Specimens of each tissue were fixed in 2.5–3.0% glutaraldehyde in 0.1 M sodium phosphate buffer pH 7.2 for 2–4 h. After rinsing in 0.1 M sodium phosphate buffer pH 7.2 containing 0.1 M sucrose half of the blocks were osmicated (1% osmium tetroxide in Millonig's phosphate buffer, pH 7.2 for 1 h). The samples were then rinsed in buffer, dehydrated through a graded series of ethanol and embedded in Araldite epoxy resin. Ultra-thin sections, showing silver to silver-grey interference colours, were mounted on cleaned, uncoated 200- or 300-mesh hexagonal nickel grids.
Electron microscopical immunocytochemistry

A modified immunoglobulin–gold staining procedure was used. Briefly, sections of osmicated tissue were treated with a saturated aqueous solution of sodium metaperiodate for 30–60 min to diminish the protein masking effect of osmium. After rinsing in PBS the grids were incubated in normal goat serum at 1:20 dilution in PBS for 30 min followed by primary antiserum for 2–3 h at room temperature, or overnight at 4°C at optimal titre (Table 2). The grids were thoroughly washed on droplets of 50 mmol Tris-HCl buffer, pH 7.2, containing 0.1% Tween 20 (3 × 5 min), 50 mmol Tris-HCl buffer, pH 7.2, containing 0.1% Tween 20 and 0.2% bovine serum albumin (BSA, Sigma fraction V, globulin-free; 2 × 5 min) and 50 mmol Tris-HCl buffer, pH 8.4, containing 0.1% Tween 20 and 1% BSA (1 × 5 min). This washing step was followed by incubation in 10 nm gold-labelled goat anti-rabbit IgG (Janssen Pharmaceutica, Beerse, Belgium) at optimal titre for 30–60 min. Excess gold-labelled reagents were washed off with 50 mmol Tris-HCl buffer, pH 7.2, containing 0.1% Tween 20 and 1% BSA (1 × 5 min). The grids were then counterstained with methanolic uranyl acetate and aqueous lead citrate before viewing in a transmission electron microscope.

Specificity controls were performed as in Table 3.

Table 3. PSN antiserum absorption test

<table>
<thead>
<tr>
<th>Peptide concentration</th>
<th>PSN</th>
<th>PSN–Tyr</th>
<th>G17</th>
<th>PSS</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 nmol ml⁻¹*</td>
<td>Completely absorbed</td>
<td>Not absorbed</td>
<td>Not absorbed</td>
<td>NT</td>
</tr>
<tr>
<td>10 nmol ml⁻¹</td>
<td>Completely absorbed</td>
<td>NT</td>
<td>NT</td>
<td>Not absorbed</td>
</tr>
<tr>
<td>1 nmol ml⁻¹</td>
<td>Partially absorbed</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>0.1 nmol ml⁻¹</td>
<td>Not absorbed</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>0.01 nmol ml⁻¹</td>
<td>Not absorbed</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
</tbody>
</table>

* nmol peptide ml⁻¹ diluted antiserum.
RESULTS

In this paper, for clarity, each antiserum is referred to by its code, i.e., antiserum PSN was raised against the C-terminal flanking nonapeptide of progastrin (progastrin 93–101; see Table 1 and Fig. 1); GL7 against a C-terminal heptapeptide (progastrin 87–93); GL9 against a C-terminal nonapeptide (progastrin 87–95). Antiserum PSS was raised against the C-terminal flanking peptide (96–104, see Table 1) of procholecystokinin (PSS). However, such a description is not meant to reflect an absolute specificity for that particular antiserum, but simply to designate the antigen used in immunization.

The results of the antiserum adsorption tests are given in Table 3. Immunostaining with an antiserum to the C-terminal flanking peptide of progastrin (PSN) could be prevented completely by pre-adsorption with 10 nmol of homologous peptide ml⁻¹ diluted antiserum, whereas the same antiserum was unaffected by 10 nmol ml⁻¹ of the C-terminal flanking peptide of procholecystokinin (PSS) and 20 nmol ml⁻¹ of PSN-tyrosine and gastrin-17. The specificities of antisera GL7 and GL9 are reported elsewhere.

Many cells reactive to antisera raised against C-terminal immunoreactants of human progastrin (PSN, GL7 and GL9) were found in the human gastric antrum (Fig. 2). These cells showed a similar distribution and number to the cells identified by antisera to gastrin-17 and gastrin-34. However, the immunostaining was localized predominantly to the perinuclear region of the G-cells, though it was not restricted to it. Antisera PSN and gastrin-17 were found to detect reactive material in the same (G) cells on semi-thin serial resin sections (Fig. 3). Hyperplastic G-cells also showed immunoreactivity to antisera PSN, GL7, GL9 and gastrin-34, but the density of immunostaining was more than that in normal G-cells (Fig. 4). At the ultrastructural level in the normal antrum, gastrin-17 antiserum was found to react with both immature (small [160–220 nm] spherical, electron-dense) and mature (large [240–320 nm], spherical, pale-cored) secretory granules (Fig. 5), as previously described. Similar results were obtained with antiserum PSN. However, in the highly active, hyperplastic G-cells only minimal immunoreactivity to antiserum PSN was observed.

In the duodenum, a few cells immunoreactive with the PSN, GL7 and GL9 antisera were observed. These cells showed a similar number and distribution to those demonstrated by the gastrin-34 antiserum; however, this finding was in distinct contrast to the large number of cells identified using the antisera to gastrin-17, some of which probably correspond to cholecystokinin-containing cells.

In foetal tissue, cells containing the C-flanking peptide of progastrin and C-terminal gastrin were present in the duodenum from 8 weeks' gestation onwards (Fig. 6). However, these cells were not seen in the stomach until 11 weeks of gestation (Fig. 7). Immunostaining on serial sections demonstrated that C-terminal gastrin (gastrin-17)-immunoreactive cells also contained PSN immunoreactivity at all stages of development. However, in later foetuses (20–28 weeks) gastrin-17-immunoreactive cells were seen more frequently than those immunostained with the antiserum to PSN.

In the islet cell tumours producing gastrin, antisera PSN, GL7, GL9, gastrin-17 and gastrin-34 revealed a similar, though variable, pattern of localization. In some cases scattered cells were stained, in others solid blocks of tumour cells (Fig. 8, Fig. 4). As in
Expression of human progastrin

Fig. 2. Human antral mucosa containing scattered cells showing immunoreactivity for PSN. (a) Low magnification (× 50) (with Nomarski optics). (b) Higher magnification (× 200).
Fig. 3. Serial semi-thin sections of resin-embedded human antrum immunostained with antisera (a) G17, (b) PSN. The same cells can be seen in both sections and showing immunoreactivity for the two portions of progastrin. Magnification \times 300.
Expression of human progastrin

Fig. 4. Antral mucosa from a patient with pernicious anaemia showing large numbers of PSN-immunoreactive cells, some of which occur in abnormal clumps (arrows). Magnification × 170.

Fig. 5. Electron micrograph of PSN immunoreactivity in a normal G-cell from human gastric antrum. Immuno-gold staining method using 10 nm gold particles. The tissue is non-osmicated. Magnification × 80,000 and (inset) × 200,000.
the hyperplastic G-cells, at the electron microscopical level, minimal immunoreactivity to antiserum PSN was obtained in G-cell tumours.

DISCUSSION

Alternative processing of genomic DNA nucleotide sequences can result in tissue-specific expression of primary transcripts, for example calcitonin in thyroid C-cells and calcitonin gene-related peptide (CGRP) in both central and peripheral nervous systems. However, there are many instances of multiple peptide sequences from single prohormones being expressed, synthesized and secreted by the same cells, for example calcitonin and katacalcin, glucagon and related peptides.

In this study we have used three antisera (PSN, GL7 and GL9) raised against peptide fragments present in the C-terminal region of the human progastrin molecule. All three antisera detected gastrin-containing cells in human adult and foetal gastric antrum and duodenum, as well as in antral G-cell hyperplasia and pancreatic islet cell tumours producing gastrin (and associated with the Zollinger–Ellison syndrome). In the normal G-cells, PSN immunoreactivity was localized predominantly to the perinuclear region which would be consistent with the intracytoplasmic site of the Golgi complex. At the ultrastructural level, no peptide immunoreactivity was observed in association with the Golgi apparatus, but this may be the result of epitope masking by unknown factors, rather than reflecting a real absence of the PSN-containing antigen.
Fig. 7. (a) Haematoxylin and eosin stained section of human foetal stomach of 11 weeks' gestation. Magnification × 20. (b) Gastric mucosa from a human foetus at 11 weeks' gestation containing scattered PSN-immunoreactive cells. Magnification × 300 (with Nomarski optics).
Gastrin has a C-terminal octapeptide homology with another gut hormone, cholecystokinin (CCK), and because of this structural similarity the two peptides have often been difficult to differentiate by immunocytochemical techniques.\(^2\) Although the C-flanking peptide of gastrin has a tetrapeptide N-terminal homology with the C-terminal flanking peptide of rat procholecystokinin (see Table 1), light microscopical immunocytochemical observations would seem to suggest that CCK cells present in the duodenum are not detected by antiserum PSN. Thus it would appear that antiserum PSN is a reliable immunological marker for true duodenal gastrin cells at the light microscopical level.

Immunoreactivities for both gastrin and C-terminal progastrin were visualized in cells of the foetal human duodenum some weeks before they were seen in the gastric mucosa. The observation of G-cells appearing first in duodenum is in agreement with the results of other workers on both developing rat and human gut.\(^23\)\textsuperscript{--}\textsuperscript{27} However, in this study gastrin was detected by immunocytochemistry at an earlier stage than has been reported previously. Immunoreactive cells were first seen at 8 weeks in the duodenum and at 11 weeks in the antrum, in contrast to 10 and 14 weeks, respectively, reported previously.\(^23\)\textsuperscript{,}\textsuperscript{27} Although these results suggest that G-cells develop first in the duodenum of the human foetus it is possible that there are G-cells in the antrum also at the 8-weeks stage but containing too little peptide to be immunostained. Certainly it has been shown in foetuses of 10 weeks and above that the gastrin content of the duodenum, as measured by radioimmunoassay, is up to 30 times that of the antrum.\(^26\)
The finding that, between 20 and 28 weeks of foetal life, relatively more cells show immunoreactivity for G-17 rather than antiserum PSN is interesting and suggest that progastrin may not be cleaved fully in developing cells. This may also be the case for the gastrin-producing tumours where at the electron microscopical level, no convincing reactivity with antiserum PSN was observed in neoplastic G-cells, which was in striking contrast to the intense labelling associated with antral G-cell secretory granules. These results may be compared with those recently reported by Pauwels et al. who performed a radioimmunoassay and chromatographic study using an antiserum recognizing the C-terminus of PSN on human gut and gastrin-producing tumour extracts. They concluded that progastrin may not be processed fully into smaller peptides in the tumour cells. Our findings thus provide circumstantial support for the contention that progastrin does not undergo differential post-translational processing in transformed and perhaps also developing G-cells.

The reasons why progastrin is not cleaved fully to N-terminally extended gastrin and free PSN peptides in neoplastic and developing cells have not been elucidated. It may be that there is abnormal production, relatively low levels or suppression by some means, of the enzyme responsible for gastrin–PSN cleavage. Abnormally high levels of progastrin production, coupled with low enzyme concentrations could also be conceived. Moreover, a recent report has raised the possibility that human progastrin may exist in two molecular forms, one phosphorylated. If progastrin cleavage is dependent upon one or other molecular form being present this could possibly account for the variability in immunostaining intensity. Thus our study indicates that antisera specific for the C-flanking peptide of progastrin are useful in distinguishing G-cells of the duodenum and for revealing variability in post-translational processing of progastrin, as seen in developing, hyperplastic and neoplastic G-cells.

ACKNOWLEDGEMENTS

The authors thank Mr Robert Hennessy for technical assistance and Miss Sandra Lock for typing the manuscript.

REFERENCES